These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36077308)

  • 1. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
    Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.
    Corrales E; Levit-Zerdoun E; Metzger P; Mertes R; Lehmann A; Münch J; Lemke S; Kowar S; Boerries M
    Cell Commun Signal; 2022 Nov; 20(1):187. PubMed ID: 36434616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
    Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
    Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
    Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
    J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
    PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H; Kong X; Ribas A; Lo RS
    Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
    Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
    Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
    Chhabra G; Ahmad N
    J Invest Dermatol; 2022 May; 142(5):1256-1259. PubMed ID: 34872726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
    Paulitschke V; Berger W; Paulitschke P; Hofstätter E; Knapp B; Dingelmaier-Hovorka R; Födinger D; Jäger W; Szekeres T; Meshcheryakova A; Bileck A; Pirker C; Pehamberger H; Gerner C; Kunstfeld R
    Mol Cancer Ther; 2015 Mar; 14(3):757-68. PubMed ID: 25612618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway.
    Alver TN; Heintz KM; Hovig E; Bøe SL
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1736. PubMed ID: 36251678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.
    Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M
    Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming chemoresistance to b-raf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid.
    Ren M; Wang L; Gao ZX; Deng XY; Shen KJ; Li YL; Ding YT; Wei CY; Gu JY
    Bioengineered; 2022 May; 13(5):13571-13586. PubMed ID: 36700470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
    Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
    Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
    Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
    Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
    Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
    J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.